---
title: "Paper Title Number 4"
collection: publications
category: conferences
permalink: /publication/2024-02-17-paper-title-number-4
---



## Selected First-Author Publications
1)	**Lal JC#**, Mao C#, Zhou Y, Gore-Panter SR, Rennison JH, Lovano BS, Castel L, Shin J, Gillinov AM, Smith JD, Barnard J, Van Wagoner DR, Luo Y, Cheng F, Chung MK. Transcriptomics-based network medicine approach identifies metformin as a repurposable drug for atrial fibrillation. **Cell Rep Med**. 2022 Oct 18;3(10):100749. doi: 10.1016/j.xcrm.2022.100749. Epub 2022 Oct 11. PMID: 36223777; PMCID: PMC9588904.
https://www.sciencedirect.com/science/article/pii/S2666379122002981?ssrnid=4102637&dgcid=SSRN_redirect_SD

2)	**Lal JC**, Margai L, Zitkovsky H, Price LL, Gonzalez S. Improving health behaviors and weight parameters with motivational interviewing and the TEEEN® program in an ethnically and socioeconomic diverse pediatric population. **American Journal of Medicine Open**, 100042 (2023).
https://doi.org:https://doi.org/10.1016/j.ajmo.2023.100042.

3) **Lal JC**, Townsend MG, Mehta AK, Oliwa M, Miller E, Sotayo A, Cheney E, Mittendorf EA, Letai A, Guerriero JL. Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer. **Breast Cancer Res.** 2021 Aug 5;23(1):83. doi: 10.1186/s13058-021-01448-1. PMID: 34353349; PMCID: PMC8340363.

4)	**Lal JC**, Brown SA, Collier P, Cheng F. A retrospective analysis of cardiovascular adverse events associated with immune checkpoint inhibitors. **CardioOncology**. 2021 May 28;7(1):19. doi: 10.1186/s40959-021-00106-x. PMID: 34049595; PMCID: PMC8161966.
https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-021-01448-1

6)	**Castrillon JA**, Eng C, Cheng F. Pharmacogenomics for immunotherapy and immune-related cardiotoxicity. Hum Mol Genet. 2020 Oct 20;29(R2):R186-R196. doi: 10.1093/hmg/ddaa137. PMID: 32620943; PMCID: PMC7574958.
   https://academic.oup.com/hmg/article/29/R2/R186/5867074?login=true



## Selected Contributions
1)	Gopal P, Yard BD, Petty A, **Lal JC**, Bera TK, Hoang TQ, Buhimschi AB, Abazeed ME. The mutational landscape of cancer's vulnerability to ionizing radiation. **Clin Cancer Res**. 2022 Oct 12:CCR-22-1914. doi: 10.1158/1078-0432.CCR-22-1914. Epub ahead of print. PMID: 36222846.
   
2)	Cheng F, Zhao J, Wang Y, Lu W, Liu Z, Zhou Y, Martin WR, Wang R, Huang J, Hao T, Yue H, Ma J, Hou Y, **Castrillon JA**, Fang J, Lathia JD, Keri RA, Lightstone FC, Antman EM, Rabadan R, Hill DE, Eng C, Vidal M, Loscalzo J. Comprehensive characterization of protein-protein interactions perturbed by disease mutations. **Nat Genet.** 2021 Mar;53(3):342-353. doi: 10.1038/s41588-020-00774-y. Epub 2021 Feb 8. PMID: 33558758; PMCID: PMC8237108.

3)	Mehta AK, Cheney EM, Hartl CA, Pantelidou C, Oliwa M, **Castrillon JA**, Lin JR, Hurst KE, Oliveira Taveira M, Johnson NT, Oldham WM, Kalocsay M, Berberich MJ, Boswell SA, Kothari A, Johnson S, Dillon DA, Lipschitz M, Rodig S, Santagata S, Garber JE, Tung N, Yelamos J, Thaxton JE, Mittendorf EA, Sorger PK, Shapiro GI, Guerriero JL.  Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer. **Nat Cancer** 2, 66–82 (2021). 

4)	Pentelidou C*, Sonzogni O*, De Oliveira Taveira M, Mehta AK, Kothari A, Wang D, Visal T, Li MK, Pinto J, **Castrillon JA**, Cheney EM, Bouwman P, Jonkers J, Rottenberg S, Guerriero JL, Wulf GM, Shapiro GI. PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer. **Cancer Discov.** 2019;9(6):722-737. doi:10.1158/2159-8290.CD-18-1218

5)	Guerriero JL, Sotayo A, Ponichtera HE, **Castrillon JA**, Pourzia A, Schad S, Johnson SF, Carrasco RD, Lazo S, Bronson RT, Davis SP, Lobera M, Nolan MA, Letai A. Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages. Nature. 2017;543(7645):428-432. doi:10.1038/nature21409
7)	Adeegbe DO, Liu Y, Lizotte PH, , Kamihara Y, Aref AR, Almonte C, Dries R, Li Y, Liu S, Wang X, Warner-Hatten T, **Castrillon J**, Yuan GC, Poudel-Neupane N, Zhang H, Guerriero JL, Han S, Awad MM, Barbie DA, Ritz J, Jones SS, Hammerman PS, Bradner JE, Quayle SN, Wong KK. Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer. **Cancer Discov.** 2017;7(8):852-867. doi:10.1158/2159-8290.CD-16-1020





